NTRA at a glance
Natera Inc (NTRA, SEC CIK 1604821) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Natera Inc (NTRA) reported revenue of $2.3 billion (up 35.9% from FY2024) and a net loss of $208.2 million. Diluted EPS was -$1.52.
- As of September 30, 2026, 38 institutional investment managers tracked by SignalX reported holding Natera Inc (NTRA) shares worth $25.5 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Sheena Jonathan on November 11, 2026 of 40 shares at $315.26 per share.
- In the last 90 days, NTRA insiders reported 0 open-market purchases ($0) and 177 open-market sales ($104.8M) on Form 4, a net sale of $104.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.3B
- +35.9% vs prior year
- Insiders · 90 days
- 0 buys · 177 sells
- Net −$104.8M
- 13F holders
- 38 funds
- $25.5B · −3 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes reported from the December 31, 2025 Form 10-K
- Carried-forward business risk: disclosed 10-K risks could materially adversely affect operations and prospects
- Market risk: adverse developments could reduce common-stock price and investor returns
- Disclosure risk: additional unknown or currently immaterial risks could materially harm results
Management Discussion & Analysis
- Quarterly revenue $794.0M, up 34.1% YoY from $592.2M
- Product revenue $790.0M, up 33.9%; oncology units 339,500 vs 211,000
- Product cost margin 64.6% vs 64.9% YoY, with net loss $59.9M vs $87.5M
- Cash $1.1B; operating cash flow $138.9M, down from $141.4M; capital spending $124.2M
- Outlook: continued net losses, heavy R&D investment, potential need for additional equity or debt financing
AI summary of the NTRA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results for quarter ended September 30, 2026 announced November 5, 2026
- Investor presentation furnished alongside earnings release, providing supplemental operating and financial detail
Item EX-99.2: Item EX-99.2
- Q3 2026 revenue $794.0M, up ~34% year over year, with total tests exceeding 1.09M
- Clinical MRD oncology volume ~316K, up >56% year over year and ~33K sequentially
Item EX-99.1: Item EX-99.1
- Q3 revenue $794.0M, up 34.1% YoY, with reported tests up 23.0% to 1,024,800
- Oncology tests 339,500, up 60.9% YoY, while clinical MRD units grew 32,700 sequentially
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026 announced on August 6, 2026
- Investor presentation accompanying earnings release, providing additional operating and financial context
Item EX-99.1: Item EX-99.1
- Q2 revenue $752.8M, up 37.7% YoY, driven by higher testing volume and average selling prices
- Tests processed 1,043,900, up 22.4%, with oncology tests up 57.2% to 296,700
Item EX-99.2: Item EX-99.2
- Q2 2026 revenue $752.8M, up ~38% year over year, with total tests exceeding 1.04M
- Clinical MRD oncology volume ~283K, up >56% year over year and ~34K sequentially, supporting Signatera growth
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Monica Bertagnolli resigned as Natera director and committee member effective July 1, 2026
- Departure tied to her new National Academy of Medicine position, not disagreement with Natera
AI summaries of NTRA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NTRA
Don't miss the next NTRA filing
- Alerts as it files. A push when NTRA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NTRA, by share count.
- Ask anything. An AI agent that reads every NTRA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Sheena Jonathan | Sell | Nov 11, 2026 | 40 | $315.26 |
| Sheena Jonathan | Sell | Nov 11, 2026 | 85 | $316.93 |
| Sheena Jonathan | Sell | Nov 11, 2026 | 145 | $317.87 |
| Sheena Jonathan | Sell | Nov 11, 2026 | 240 | $319.77 |
| Sheena Jonathan | Sell | Nov 11, 2026 | 160 | $320.02 |
| Sheena Jonathan | Sell | Nov 11, 2026 | 40 | $322.00 |
| Sheena Jonathan | Sell | Nov 11, 2026 | 40 | $323.06 |
| Sheena Jonathan | Sell | Nov 11, 2026 | 40 | $315.28 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.7B | $2.3B |
| Operating Income | - | -$222.3M | -$309.9M |
| Net Income | -$434.8M | -$190.4M | -$208.2M |
| Op. Margin | - | -13.1% | -13.4% |
| Net Margin | - | -11.2% | -9.0% |
| Balance Sheet | |||
| Total Assets | - | $1.7B | $2.4B |
| Equity | $765.3M | $1.2B | $1.7B |
| ROE | -56.8% | -15.9% | -12.2% |
| Per Share | |||
| EPS | - | $-1.53 | $-1.52 |
| Cash Flow | |||
| Operating CF | -$247.0M | $135.7M | $215.3M |
| CapEx | $39.2M | $66.4M | $106.2M |
Source: XBRL data in Natera Inc (NTRA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate NTRA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 38 | $25.51B |
| Q2 2026 | 41 | $19.08B |
| Q1 2026 | 40 | $13.43B |
| Q4 2025 | 38 | $14.73B |
| Q3 2025 | 37 | $12.77B |
| Q2 2025 | 35 | $11.46B |
| Q1 2025 | 33 | $5.92B |
| Q4 2024 | 30 | $4.97B |
- JPMorgan Chase & Co+1.17M (+9%)
- Invesco Ltd+212.8K (+24%)
- Bank of America Corp+181.6K (+25%)
- Citigroup+91.6K (+42%)
- Two Sigma Investments+77.8K (+239%)
- T. Rowe Price Group−2.24M (-25%)
- Goldman Sachs Group−921.2K (-54%)
- BlackRock−304.1K (-3%)
- Principal Financial Group−151.5K (-58%)
- ARK Investment Management−142.7K (-21%)
- Blackstone Group+12.1K
- FMR LLC (Fidelity)−5.45M
- Viking Global Investors−390.7K
- Citadel Advisors LLC−265.6K
- Regions Financial Corporation−857
Source: 13F-HR filings on SEC EDGAR (aggregated from 292 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NTRA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Oct 30, 2026 | - | - | - |
| 4 | Oct 29, 2026 | - | - | - |
| 4 | Oct 29, 2026 | - | - | - |
| 4 | Oct 29, 2026 | - | - | - |
| 4 | Oct 29, 2026 | - | - | - |
| 4 | Oct 29, 2026 | - | - | - |
| 4 | Oct 29, 2026 | - | - | - |
| 4 | Oct 29, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 20, 2026 | - | - | - |
| 4 | Oct 16, 2026 | - | - | - |
| 4 | Oct 9, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
Related Health Care companies
- CDNA · CareDx, Inc.Services-Medical Laboratories
- CSTL · CASTLE BIOSCIENCES INCServices-Medical Laboratories
- CELC · Celcuity Inc.Services-Medical Laboratories
- FTRE · Fortrea Holdings Inc.Services-Medical Laboratories
- FLGT · Fulgent Genetics, Inc.Services-Medical Laboratories
- GRAL · GRAIL, Inc.Services-Medical Laboratories
- GH · Guardant Health, Inc.Services-Medical Laboratories
- LH · LabcorpServices-Medical Laboratories
NTRA SEC filings: frequently asked questions
Are NTRA insiders buying or selling?
In the last 90 days, Natera Inc (NTRA) officers, directors and 10% owners reported no open-market purchases and 177 open-market sales worth $104.8 million by 7 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold NTRA stock?
As of September 30, 2026, the largest Natera Inc (NTRA) holders among the 13F filers tracked by SignalX were JPMorgan Chase & Co ($5.8 billion), BlackRock ($4.4 billion), T. Rowe Price Group ($2.8 billion), Vanguard Capital Management LLC ($2.6 billion), Vanguard Portfolio Management LLC ($2.4 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NTRA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Natera Inc (NTRA) reported revenue of $2.3 billion (up 35.9% from FY2024) and a net loss of $208.2 million. Diluted EPS was -$1.52. The figures come from the XBRL data in the 10-K.
What did NTRA report in its latest 8-K?
Natera Inc (NTRA) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results for quarter ended September 30, 2026 announced November 5, 2026.
What are the latest NTRA SEC filings?
Natera Inc (NTRA) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 13, 2026.
What is NTRA's SEC CIK number?
Natera Inc (NTRA)'s SEC Central Index Key (CIK) is 1604821. EDGAR lists every NTRA filing under that number.
Ask anything about NTRA
The research agent reads NTRA's filings, financials, insider trades and 13F holders, then answers with sources.